Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase

Christos Fokoloros; Periklis Foukas; Nikolaos Georgakopoulos; Zoi Tsakiraki; Anthi Bouchla; Vasilliki Pappa; Alexandros Katoulis; Michael Makris; Sotirios Papageorgiou

doi:10.1155/2022/7251658

Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase

Case Rep Hematol. 2022 Nov 3:2022:7251658. doi: 10.1155/2022/7251658. eCollection 2022.

Authors

Christos Fokoloros¹, Periklis Foukas², Nikolaos Georgakopoulos³, Zoi Tsakiraki², Anthi Bouchla⁴, Vasilliki Pappa⁴, Alexandros Katoulis¹, Michael Makris¹, Sotirios Papageorgiou³

Affiliations

¹ Allergy Unit "D. Kalogeromitros", 2nd Department of Dermatology and Venereology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
² 2nd Department of Pathology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.
³ Department of Cytogenetics and Molecular Pathology, Locus Medicus S.A., Athens, Greece.
⁴ Hematology Unit, 2nd Department of Internal Medicine, Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece.

Abstract

Systemic mastocytosis (SM) comprises a group of rare disorders resulting from tissue infiltration by pathological mast cells. In a percentage ranging from 5 to 40% in various patient series, SM appears to be associated with an accompanying hematologic neoplasm (SM-AHN). The coexistence of SM with chronic myelogenous leukemia (CML) is extremely rare with only 3 cases in the literature. The natural course of CML has changed dramatically over the past 2 decades with the use of tyrosine kinase inhibitors (TKIs). We report a case of diagnosing SM in a patient in complete molecular remission of CML after stopping TKI treatment.

Publication types

Case Reports